Amazingly, diabetics placed on metformin may live longer lives than those who never got diabetes in the first place.
Does Metformin Work as a Life-Extension Drug?
Below is an approximation of this video’s audio content. To see any graphs, charts, graphics, images, and quotes to which Dr. Greger may be referring, watch the above video.
Intro: Might the diabetes drug, Metformin, have an anti-aging effect? Check out this three-video series to see what the science says.
The noxious weed goat’s rue was widely used as herbal medicine back in the Middle Ages for thirst and frequent urination, what we now know as a cardinal symptom and sign of diabetes. The plant produces a mitochondrial poison known as galegine. One can imagine how this could help discourage grazing herbivores, but why would crippling mitochondrial function help with diabetes? If you got the dose just right, you could impair energy production just enough to spring AMPK into action. AMPK would then dial down the liver’s energy-intensive process of sugar production, and blood sugars would fall.
Galegine proved too toxic for use in humans (and presumably goats), but was tweaked into a milder form in the 1950s. That’s the origin story of metformin––now, even 60+ years later, the most widely prescribed diabetes drug in the world. Sold originally as Glucophage (meaning “sugar eater”), metformin is now prescribed annually more than 90 million times in the U.S. alone. Despite all the strides in biotechnology, Big Pharma has yet to come up with a safer, more effective first-line treatment for type 2 diabetes than a drug that retails at pennies per pill.
Ramping up AMPK isn’t all that metformin does (for example, it also appears to foster the growth of good bacteria in the gut). But, the AMPK boost alone would be expected to have wide-ranging health effects. Remember, AMPK is activated when resources are scarce. So, it causes the body to hunker down into energy-conservation mode, and put the brakes on new construction projects. So, no more making excess blood sugar or cholesterol. Time to start tapping into the larder. And, indeed, metformin doesn’t just lower sugars in the blood, but cholesterol and body fat. And, shutting down the excess synthesis of proteins can also have health benefits.
Fibrosis is the accumulation of scar tissue in response to an inflammatory insult. As a transient, localized phenomenon, fibrosis helps heal wounds and repair damaged tissue. But in response to the systemic inflammation of aging, surplus scar tissue can build up in our heart, liver, kidneys, and lungs. Excess fibrosis is estimated to contribute to 45 percent of all deaths in the United States. But AMPK switches the body into miser mode, shrinking the energy budget for such superfluous activities, and ratchets down fibrotic processes.
The AMPK priorities shift from growth to preservation might also be expected to slow cancer progression. Based on dozens of observational studies involving tens of thousands of diabetic cancer patients, those on metformin did indeed experience a significant survival advantage, correlating with a 26 percent decreased risk of dying from cancer. No wonder there are more than 100 ongoing studies to put metformin to the test against cancer. As the director of Harvard’s Cancer Center put it, “Metformin may have already saved more people from cancer deaths than any drug in history.”
If AMPK plays such a key role in the aging process, and metformin boosts AMPK, can metformin slow aging and lengthen lifespans? It certainly can in some species. C. elegans worms fed metformin maintain a youthful state, and can exhibit a nearly 40 percent increase in average survival. Interfere with the AMPK pathway, though, and this lifespan extension disappears, confirming the role of AMPK in metformin’s anti-aging effects. Metformin also improves the healthspans and lifespans of mice, but failed to extend the lives of rats, calling the pro-longevity effects of metformin into question.
The dose they used (15 times that used in humans) may have been too high, however, and the F344 rats they used are an inbred strain (named after the 344th brother–sister mating) that are resistant to the health benefits of calorie restriction. Since metformin acts through AMPK as a calorie restriction mimetic, it stands to reason that these animals may be less prone to metformin’s effects. What about humans?
Unlike other potential anti-aging drugs in the pipeline, we have the benefit of data on more than a million study subjects who have been tracked in metformin trials. And, indeed, compared to diabetics who take drugs other than metformin, those on metformin appear protected from age-related susceptibilities like fractures or serious infection, glaucoma, and cognitive impairment.
Most importantly, diabetics who take metformin live significantly longer than those taking different sugar-lowering drugs. Doesn’t that prove metformin is a pro-longevity drug? No. For example, maybe metformin just controlled their diabetes better. Researchers still found a survival benefit for diabetics on metformin compared to those as well managed on other drugs, but maybe the other drugs were shortening lifespans, and so, metformin just looked good in comparison. How could you try to tease out the effects?
What if you compared the lifespans of diabetics on metformin to nondiabetics? Now, that’s not really a fair comparison. Any benefits metformin has could easily be outweighed and masked by the life-limiting nature of diabetes—unless, that is, the diabetics on metformin actually lived longer. Longer than nondiabetics. And, are you sitting down? That’s exactly what the research shows. Diabetics placed on metformin went on to live longer lives than those who never got diabetes in the first place. From a longevity standpoint, it’s as if they got lucky to be diagnosed with diabetes, because then, they had access to this lifespan-enhancing drug. So, wait. If metformin is so powerful as to more than offset such a dreaded diagnosis, should everyone be taking metformin? What are the downsides? That’s exactly what I’m going to be covering next.
Please consider volunteering to help out on the site.
- Torres W, Nava M, Galbán N, et al. Anti-aging effect of metformin: a molecular and therapeutical perspective. Curr Pharm Des. 2020;26(35):4496-4508.
- Hardie DG. Keeping the home fires burning: AMP-activated protein kinase. J R Soc Interface. 2018;15(138):20170774.
- Bailey CJ. Metformin: historical overview. Diabetologia. 2017;60(9):1566-1576.
- The Top 200 Drugs of 2020. ClinCalc DrugStats Database. 2022.
- Inzucchi SE, Fonseca V. Dethroning the king?: The future of metformin as first line therapy in type 2 diabetes. J Diabetes Complications. 2019;33(6):462-464.
- Prattichizzo F, Giuliani A, Mensà E, et al. Pleiotropic effects of metformin: Shaping the microbiome to manage type 2 diabetes and postpone ageing. Ageing Research Reviews. 2018;48:87-98.
- McCarty MF. AMPK activation--protean potential for boosting healthspan. Age (Dordr). 2014;36(2):641-663.
- Solymár M, Ivic I, Pótó L, et al. Metformin induces significant reduction of body weight, total cholesterol and LDL levels in the elderly - A meta-analysis. PLoS One. 2018;13(11):e0207947.
- Jiang S, Li T, Yang Z, et al. AMPK orchestrates an elaborate cascade protecting tissue from fibrosis and aging. Ageing Res Rev. 2017;38:18-27.
- Cao X, Wu Y, Wang J, Liu K, Wang X. The effect of metformin on mortality among diabetic cancer patients: a systematic review and meta-analysis. JNCI Cancer Spectr. 2017;1(1):pkx007.
- Newman JC, Milman S, Hashmi SK, et al. Strategies and challenges in clinical trials targeting human aging. J Gerontol A Biol Sci Med Sci. 2016;71(11):1424-1434.
- Taubes G. Cancer prevention with a diabetes pill? Science. 2012;335(6064):29-29.
- Ruiz R, Pérez-Villegas EM, Manuel Carrión Á. AMPK function in aging process. Curr Drug Targets. 2016;17(8):932-941.
- Onken B, Driscoll M. Metformin induces a dietary restriction-like state and the oxidative stress response to extend C. elegans Healthspan via AMPK, LKB1, and SKN-1. PLoS One. 2010;5(1):e8758.
- Martin-Montalvo A, Mercken EM, Mitchell SJ, et al. Metformin improves healthspan and lifespan in mice. Nat Commun. 2013;4:2192.
- Smith DL, Elam CF, Mattison JA, et al. Metformin supplementation and life span in Fischer-344 rats. J Gerontol A Biol Sci Med Sci. 2010;65(5):468-474.
- Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell Metab. 2016;23(6):1060-1065.
- Novelle MG, Ali A, Diéguez C, Bernier M, de Cabo R. Metformin: a hopeful promise in aging research. Cold Spring Harb Perspect Med. 2016;6(3):a025932.
- Han Y, Xie H, Liu Y, Gao P, Yang X, Shen Z. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol. 2019;18(1):96.
- Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (Adopt). Diabetes Care. 2008;31(5):845-851.
- Mor A, Petersen I, Sørensen HT, Thomsen RW. Metformin and other glucose-lowering drug initiation and rates of community-based antibiotic use and hospital-treated infections in patients with type 2 diabetes: a Danish nationwide population-based cohort study. BMJ Open. 2016;6(8):e011523.
- Lin HC, Stein JD, Nan B, et al. Association of geroprotective effects of metformin and risk of open-angle glaucoma in persons with diabetes mellitus. JAMA Ophthalmol. 2015;133(8):915-923.
- Ng TP, Feng L, Yap KB, Lee TS, Tan CH, Winblad B. Long-term metformin usage and cognitive function among older adults with diabetes. J Alzheimers Dis. 2014;41(1):61-68.
- Campbell JM, Bellman SM, Stephenson MD, Lisy K. Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis. Ageing Res Rev. 2017;40:31-44.
Motion graphics by Avo Media
Below is an approximation of this video’s audio content. To see any graphs, charts, graphics, images, and quotes to which Dr. Greger may be referring, watch the above video.
Intro: Might the diabetes drug, Metformin, have an anti-aging effect? Check out this three-video series to see what the science says.
The noxious weed goat’s rue was widely used as herbal medicine back in the Middle Ages for thirst and frequent urination, what we now know as a cardinal symptom and sign of diabetes. The plant produces a mitochondrial poison known as galegine. One can imagine how this could help discourage grazing herbivores, but why would crippling mitochondrial function help with diabetes? If you got the dose just right, you could impair energy production just enough to spring AMPK into action. AMPK would then dial down the liver’s energy-intensive process of sugar production, and blood sugars would fall.
Galegine proved too toxic for use in humans (and presumably goats), but was tweaked into a milder form in the 1950s. That’s the origin story of metformin––now, even 60+ years later, the most widely prescribed diabetes drug in the world. Sold originally as Glucophage (meaning “sugar eater”), metformin is now prescribed annually more than 90 million times in the U.S. alone. Despite all the strides in biotechnology, Big Pharma has yet to come up with a safer, more effective first-line treatment for type 2 diabetes than a drug that retails at pennies per pill.
Ramping up AMPK isn’t all that metformin does (for example, it also appears to foster the growth of good bacteria in the gut). But, the AMPK boost alone would be expected to have wide-ranging health effects. Remember, AMPK is activated when resources are scarce. So, it causes the body to hunker down into energy-conservation mode, and put the brakes on new construction projects. So, no more making excess blood sugar or cholesterol. Time to start tapping into the larder. And, indeed, metformin doesn’t just lower sugars in the blood, but cholesterol and body fat. And, shutting down the excess synthesis of proteins can also have health benefits.
Fibrosis is the accumulation of scar tissue in response to an inflammatory insult. As a transient, localized phenomenon, fibrosis helps heal wounds and repair damaged tissue. But in response to the systemic inflammation of aging, surplus scar tissue can build up in our heart, liver, kidneys, and lungs. Excess fibrosis is estimated to contribute to 45 percent of all deaths in the United States. But AMPK switches the body into miser mode, shrinking the energy budget for such superfluous activities, and ratchets down fibrotic processes.
The AMPK priorities shift from growth to preservation might also be expected to slow cancer progression. Based on dozens of observational studies involving tens of thousands of diabetic cancer patients, those on metformin did indeed experience a significant survival advantage, correlating with a 26 percent decreased risk of dying from cancer. No wonder there are more than 100 ongoing studies to put metformin to the test against cancer. As the director of Harvard’s Cancer Center put it, “Metformin may have already saved more people from cancer deaths than any drug in history.”
If AMPK plays such a key role in the aging process, and metformin boosts AMPK, can metformin slow aging and lengthen lifespans? It certainly can in some species. C. elegans worms fed metformin maintain a youthful state, and can exhibit a nearly 40 percent increase in average survival. Interfere with the AMPK pathway, though, and this lifespan extension disappears, confirming the role of AMPK in metformin’s anti-aging effects. Metformin also improves the healthspans and lifespans of mice, but failed to extend the lives of rats, calling the pro-longevity effects of metformin into question.
The dose they used (15 times that used in humans) may have been too high, however, and the F344 rats they used are an inbred strain (named after the 344th brother–sister mating) that are resistant to the health benefits of calorie restriction. Since metformin acts through AMPK as a calorie restriction mimetic, it stands to reason that these animals may be less prone to metformin’s effects. What about humans?
Unlike other potential anti-aging drugs in the pipeline, we have the benefit of data on more than a million study subjects who have been tracked in metformin trials. And, indeed, compared to diabetics who take drugs other than metformin, those on metformin appear protected from age-related susceptibilities like fractures or serious infection, glaucoma, and cognitive impairment.
Most importantly, diabetics who take metformin live significantly longer than those taking different sugar-lowering drugs. Doesn’t that prove metformin is a pro-longevity drug? No. For example, maybe metformin just controlled their diabetes better. Researchers still found a survival benefit for diabetics on metformin compared to those as well managed on other drugs, but maybe the other drugs were shortening lifespans, and so, metformin just looked good in comparison. How could you try to tease out the effects?
What if you compared the lifespans of diabetics on metformin to nondiabetics? Now, that’s not really a fair comparison. Any benefits metformin has could easily be outweighed and masked by the life-limiting nature of diabetes—unless, that is, the diabetics on metformin actually lived longer. Longer than nondiabetics. And, are you sitting down? That’s exactly what the research shows. Diabetics placed on metformin went on to live longer lives than those who never got diabetes in the first place. From a longevity standpoint, it’s as if they got lucky to be diagnosed with diabetes, because then, they had access to this lifespan-enhancing drug. So, wait. If metformin is so powerful as to more than offset such a dreaded diagnosis, should everyone be taking metformin? What are the downsides? That’s exactly what I’m going to be covering next.
Please consider volunteering to help out on the site.
- Torres W, Nava M, Galbán N, et al. Anti-aging effect of metformin: a molecular and therapeutical perspective. Curr Pharm Des. 2020;26(35):4496-4508.
- Hardie DG. Keeping the home fires burning: AMP-activated protein kinase. J R Soc Interface. 2018;15(138):20170774.
- Bailey CJ. Metformin: historical overview. Diabetologia. 2017;60(9):1566-1576.
- The Top 200 Drugs of 2020. ClinCalc DrugStats Database. 2022.
- Inzucchi SE, Fonseca V. Dethroning the king?: The future of metformin as first line therapy in type 2 diabetes. J Diabetes Complications. 2019;33(6):462-464.
- Prattichizzo F, Giuliani A, Mensà E, et al. Pleiotropic effects of metformin: Shaping the microbiome to manage type 2 diabetes and postpone ageing. Ageing Research Reviews. 2018;48:87-98.
- McCarty MF. AMPK activation--protean potential for boosting healthspan. Age (Dordr). 2014;36(2):641-663.
- Solymár M, Ivic I, Pótó L, et al. Metformin induces significant reduction of body weight, total cholesterol and LDL levels in the elderly - A meta-analysis. PLoS One. 2018;13(11):e0207947.
- Jiang S, Li T, Yang Z, et al. AMPK orchestrates an elaborate cascade protecting tissue from fibrosis and aging. Ageing Res Rev. 2017;38:18-27.
- Cao X, Wu Y, Wang J, Liu K, Wang X. The effect of metformin on mortality among diabetic cancer patients: a systematic review and meta-analysis. JNCI Cancer Spectr. 2017;1(1):pkx007.
- Newman JC, Milman S, Hashmi SK, et al. Strategies and challenges in clinical trials targeting human aging. J Gerontol A Biol Sci Med Sci. 2016;71(11):1424-1434.
- Taubes G. Cancer prevention with a diabetes pill? Science. 2012;335(6064):29-29.
- Ruiz R, Pérez-Villegas EM, Manuel Carrión Á. AMPK function in aging process. Curr Drug Targets. 2016;17(8):932-941.
- Onken B, Driscoll M. Metformin induces a dietary restriction-like state and the oxidative stress response to extend C. elegans Healthspan via AMPK, LKB1, and SKN-1. PLoS One. 2010;5(1):e8758.
- Martin-Montalvo A, Mercken EM, Mitchell SJ, et al. Metformin improves healthspan and lifespan in mice. Nat Commun. 2013;4:2192.
- Smith DL, Elam CF, Mattison JA, et al. Metformin supplementation and life span in Fischer-344 rats. J Gerontol A Biol Sci Med Sci. 2010;65(5):468-474.
- Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell Metab. 2016;23(6):1060-1065.
- Novelle MG, Ali A, Diéguez C, Bernier M, de Cabo R. Metformin: a hopeful promise in aging research. Cold Spring Harb Perspect Med. 2016;6(3):a025932.
- Han Y, Xie H, Liu Y, Gao P, Yang X, Shen Z. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol. 2019;18(1):96.
- Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (Adopt). Diabetes Care. 2008;31(5):845-851.
- Mor A, Petersen I, Sørensen HT, Thomsen RW. Metformin and other glucose-lowering drug initiation and rates of community-based antibiotic use and hospital-treated infections in patients with type 2 diabetes: a Danish nationwide population-based cohort study. BMJ Open. 2016;6(8):e011523.
- Lin HC, Stein JD, Nan B, et al. Association of geroprotective effects of metformin and risk of open-angle glaucoma in persons with diabetes mellitus. JAMA Ophthalmol. 2015;133(8):915-923.
- Ng TP, Feng L, Yap KB, Lee TS, Tan CH, Winblad B. Long-term metformin usage and cognitive function among older adults with diabetes. J Alzheimers Dis. 2014;41(1):61-68.
- Campbell JM, Bellman SM, Stephenson MD, Lisy K. Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis. Ageing Res Rev. 2017;40:31-44.
Motion graphics by Avo Media
Republishing "Does Metformin Work as a Life-Extension Drug?"
You may republish this material online or in print under our Creative Commons licence. You must attribute the article to NutritionFacts.org with a link back to our website in your republication.
If any changes are made to the original text or video, you must indicate, reasonably, what has changed about the article or video.
You may not use our material for commercial purposes.
You may not apply legal terms or technological measures that restrict others from doing anything permitted here.
If you have any questions, please Contact Us
Does Metformin Work as a Life-Extension Drug?
LicenseCreative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)
Content URLDoctor's Note
This is the third video in a five-part series. If you missed the first two, see Naturally Boosting AMPK with Caloric Restriction for Life Extension and Naturally Boosting AMPK with Exercise for Life Extension.
Stay tuned for Side Effects of Metformin as a Life-Extension Drug and The TAME Trial: Targeting Aging with Metformin.
AMPK is one of the anti-aging pathways I highlight in my longevity book, How Not to Age, available in print, e-book, and audio. (All proceeds I receive from the book are donated directly to charity.)
If you haven't yet, you can subscribe to our free newsletter. With your subscription, you'll also get notifications for just-released blogs and videos. Check out our information page about our translated resources.